Summary The chemosensitising effect of the nitroaromatic radiosensitiser misonidazole (MISO) on the alkylating agent cyclophosphamide (CTX) has been investigated in a C3H mammary carcinoma in CDF, mice.
The ability of nitroimidazoles to enhance the tumour response of anti-cancer drugs has been shown by several investigators in different animal models (see review by Siemann, 1982) and is currently being investigated in phase II clinical trials. However, the mechanisms underlying the observed chemosensitisation in vivo is still not settled, although several suggestions have been made. These include the preferential killing of hypoxic cells by the nitroimidazole, changes in the pharmacokinetics and metabolism of the cancer chemotherapeutic drug, interference with the repair of potentially lethal damage and a manifestation of the in vitro pre-incubation effect observed under hypoxic conditions (Brown, 1982; Siemann, 1982 . In vitro, hypoxia has been found to be a prerequisite for chemopotentiation to occur. No effect has been observed if cells were exposed to the sensitiser under aerobic conditions, unless extremely high doses were used (Smith et al., 1982) . Some studies in vivo have also suggested that hypoxia plays a role in the development of chemosensitisation. The observation is primarily based on a relationship between the amount of sensitisation observed and the degree of tumour hypoxia Wheeler et al., 1984) . However, the observed sensitisation generally exceeds what would be expected if the interaction between the sensitiser and the drug was restricted to the radiobiologically hypoxic tumour cell population (Brown & Hirst, 1982; Hinchliffe et al., 1983; Horsman et al., 1984) . Thus the importance of hypoxic conditions for chemosensitisation in vivo is still unsettled.
The aim of the present study was to investigate the selective effect of MISO and the alkylating agent cyclophosphamide (CTX) on aerobic and hypoxic cells in situ, using a clamped local tumour control assay applied to a C3H mouse mammary carcinoma.
Materials and methods

Animal tumour system
The C3H/Tif mammary carcinoma was grown in the right rear foot of 10-12-week-old male C3D2F1 mice. Nonanaesthetised mice were treated when tumours were on average 200 mm3 (in the range 150-257 mm3), determined by the formula: n/6 x Dl x D2 x D3, where the Ds represent the three orthogonal diameters.
Irradiation
Irradiation was given as single doses with 250 kV X-rays (lOmA, HVL 3.1 mm Cu, dose rate 2.26Gymin-'). The mice were placed in a lucite jig with the tumour-bearing leg exposed, loosely taped to the jig and immersed in a water bath to ensure a homogeneous dose distribution in the tumour. Animals receiving X-rays under hypoxic conditions had the tumour-bearing leg clamped 5 min before and during the period of irradiation. Clamping was achieved by constriction of the blood flow using a rubber tube tightened around the leg. The validity of this procedure to generate complete radiobiological hypoxia has been documented previously (Grau & Overgaard, 1988) .
Drugs
MISO was dissolved in isotonic saline at room temperature and administered intraperitoneally (i.p.) in a volume of 0.04 ml g-' body weight. CTX was dissolved in sterile distilled water and injected i.p. at a volume of 0.02 ml g-' body weight. MISO was given 4 h after irradiation, followed by CTX 15 min later.
Tumour growth delay
The tumour volume was measured daily and the response evaluated in terms of tumour growth time (TGT), defined as the time required for a tumour to reach three times treatment volume. The exponential regrowth phase was used to calculate the volume doubling time (DT). All calculations were based on individual growth data.
Local tumour control
The effect of graded doses of radiation alone or in combination with drugs was evaluated as the radiation dose required to produce local tumour control in 50% of the treated animals (TCD50). Tumour control was defined as complete absence of macroscopic relapse within 90 days. Data were analysed using a Logit analysis (Suit et al., 1965) .
Hypoxic fraction
The proportion of radiobiologically hypoxic tumour cells, the hypoxic fraction (HF), was calculated from the local tumour control data as described in the Appendix. The validity of the biological assumptions underlying these formulae have been discussed in details in a previous paper (Grau & Overgaard, 1988) . In short, the HF was calculated from the horizontal distance between TCD^o curves for tumours irradiated under aerobic or clamped conditions and the D. for hypoxic cells.
The total number of tumour cells (N) was calculated from the TCD50 values, as also described in the Appendix. Based on drug-induced changes in HF and N, the surviving fraction (SF) of aerobic and hypoxic cells was calculated. Statistical analysis was done by the propagation-of-error technique.
Results
The influence of the clamping procedure on drug access and toxicity was tested in a tumour regrowth delay study (Table  I) (Moore et al., 1976; Sutherland et al., 1982) . CTX was found to be more toxic towards hypoxic than aerobic cells, as previously reported from our laboratory (Grau & Overgaard, 1988 (Grau et al., 1990) . From tumour regrowth delay data a significant supra-additive drug effect was found. This might reflect an enhanced effect on aerobic cells, since oxygenated cells are believed to dominate the overall tumour growth. On the other hand the druginduced modification of radiation response (in terms of local tumour control) was purely additive, suggesting that there was no synergistic effect on radioresistant hypoxic cells.
Although the exact mechanism is still unsettled, the presence of hypoxia has been suggested to be critical for the development of chemosensitisation observed in vitro . Until now no direct evidence for this requirement of hypoxia in vivo has been presented. Some indirect evidence exists, suggesting that hypoxia plays a role. Tumours with small hypoxic fractions show less enhanced damage to drugs than do the same tumours with larger hypoxic fractions. (Martin et al., 1981; Sheldon & Batten, 1982; Spooner et al., 1982) . Tumours that lack radiobiologically hypoxic cells show no chemopotentiation unless they are made artifically hypoxic between MISO injection and treatment with BCNU (Wheeler et al., 1984) . However, the observed sensitisation exceeds what would be expected if the interaction between MISO and alkylating drugs is restricted to the small fraction of clonogenic and radiobiologically hypoxic tumour cells (Brown & Hirst, 1982; Hinchliffe et al., 1983; Horsman et al., 1984) . So, while hypoxia appears to be necessary for the chemosensitisation to occur, significant effects can be seen in cells at oxygenation levels above what would render them radiobiologically hypoxic. This has been demonstrated by several investigators. Durand and Chaplin (1987) used the fluorochrome Hoechst 33342 to separate tumour cells in fractions as a function of distance from the blood vessels. They found that the chemosensitisation by MISO in KHT tumours treated wth CCNU was almost constant throughout the tumour, irrespective of the oxygenation status of the cells. In vitro the dependence of chemosensitisation by MISO on oxygen concentration has been examined (Mulcahy, 1984; Roizin-Towle et al., 1986 (Howes, 1969) , described by the multi-hit cell-survival model with identical extrapolation number, n, and slope of the log-linear part of the survival curve, Do. D. was taken to be 3.2 Gy (Suit et al., 1965 Assuming the tumour control probability to be determined solely from the radiosensitivity of the hypoxic tumour clonogens, the number of hypoxic tumour clonogens, Nh, is estimated as:
The factor 1 n(2)/3 is exp(l n(1 n(2)) -In(n)) in the derivation by Suit et al. (1965) , assuming the extrapolation number n in the multi-hit cell-survival model to be equal to 3.
The standard error of Nh may be estimated by: s.e. 
The standard error of HF is estimated by: 
